> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Positive Data on Pneumococcal Conjugate Vaccine
- URL: https://www.fdaweb.com/merck-positive-data-on-pneumococcal-conjugate-vaccine/
- Published: 2020-10-20T12:00:00.000Z
- Updated: 2026-09-14T16:33:21.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5147907

Merck has [announced](https://seekingalpha.com/pr/18049528-merck-announces-positive-topline-results-from-two-additional-phase-3-adult-studies-evaluating?ref=fdaweb.com) positive findings from two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. Data from the PNEU-PATH (V114-016) and PNEU-DAY (V114-017) studies showed favorable immune responses. “Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies,” the company says. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies, it says. Findings will be presented at a future scientific meeting, and the company says a BLA will be filed before the end of the year.